{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:03Z","timestamp":1783646103614,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071392"],"award-info":[{"award-number":["82071392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ph.D Youth Foundation of the second affiliated hospital, Army Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10101-6","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:00:10Z","timestamp":1778047210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive genome editing and signaling pathway engineering evolve potent and safe adenoviral producer cell"],"prefix":"10.1038","volume":"9","author":[{"given":"Zhe","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Ze","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-8187","authenticated-orcid":false,"given":"Sen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1740-5241","authenticated-orcid":false,"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"10101_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10101_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target Ther. 8, 156 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"10101_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10101_CR4","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","volume":"10","author":"W Lu","year":"2004","unstructured":"Lu, W. et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol. 10, 3634\u20133638 (2004).","journal-title":"World J. Gastroenterol."},{"key":"10101_CR5","first-page":"1666","volume":"23","author":"ZJ Xia","year":"2004","unstructured":"Xia, Z. J. et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng 23, 1666\u20131670 (2004).","journal-title":"Ai Zheng"},{"key":"10101_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.272.5267.1470","volume":"272","author":"T Dobner","year":"1996","unstructured":"Dobner, T., Horikoshi, N., Rubenwolf, S. & Shenk, T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470\u20131473 (1996).","journal-title":"Science"},{"key":"10101_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479\u2013488 (2020).","journal-title":"Lancet"},{"key":"10101_CR8","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"10101_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"10101_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106733","volume":"26","author":"CS Benn","year":"2023","unstructured":"Benn, C. S., Schaltz-Buchholzer, F., Nielsen, S., Netea, M. G. & Aaby, P. Randomized clinical trials of COVID-19 vaccines: do adenovirus-vector vaccines have beneficial non-specific effects? iScience 26, 106733 (2023).","journal-title":"iScience"},{"key":"10101_CR11","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn, I. et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409 (2008).","journal-title":"PLoS ONE"},{"key":"10101_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","volume":"7","author":"JP Machiels","year":"2019","unstructured":"Machiels, J. P. et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J. Immunother. Cancer 7, 20 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"10101_CR13","doi-asserted-by":"publisher","unstructured":"Moreno, V. et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2021-003645 (2021).","DOI":"10.1136\/jitc-2021-003645"},{"key":"10101_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76137-8","volume":"10","author":"M Malm","year":"2020","unstructured":"Malm, M. et al. Evolution from adherent to suspension: systems biology of HEK293 cell line development. Sci. Rep. 10, 18996 (2020).","journal-title":"Sci. Rep."},{"key":"10101_CR15","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/v2081681","volume":"2","author":"I Kovesdi","year":"2010","unstructured":"Kovesdi, I. & Hedley, S. J. Adenoviral producer cells. Viruses 2, 1681\u20131703 (2010).","journal-title":"Viruses"},{"key":"10101_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1006\/viro.1997.8597","volume":"233","author":"N Louis","year":"1997","unstructured":"Louis, N., Evelegh, C. & Graham, F. L. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423\u2013429 (1997).","journal-title":"Virology"},{"key":"10101_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59\u201374 (1977).","journal-title":"J. Gen. Virol."},{"key":"10101_CR18","doi-asserted-by":"publisher","first-page":"8459","DOI":"10.1128\/jvi.70.12.8459-8467.1996","volume":"70","author":"KM Hehir","year":"1996","unstructured":"Hehir, K. M. et al. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70, 8459\u20138467 (1996).","journal-title":"J. Virol."},{"key":"10101_CR19","doi-asserted-by":"publisher","unstructured":"Lian, X. et al. A new HEK293 cell with CR2 region of E1A gene deletion prevents the emergence of replication-competent adenovirus. Cancers 15, https:\/\/doi.org\/10.3390\/cancers15245713 (2023).","DOI":"10.3390\/cancers15245713"},{"key":"10101_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/hum.1996.7.2-215","volume":"7","author":"FJ Fallaux","year":"1996","unstructured":"Fallaux, F. J. et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7, 215\u2013222 (1996).","journal-title":"Hum. Gene Ther."},{"key":"10101_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","volume":"9","author":"FJ Fallaux","year":"1998","unstructured":"Fallaux, F. J. et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909\u20131917 (1998).","journal-title":"Hum. Gene Ther."},{"key":"10101_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/emm.2001.25","volume":"33","author":"JS Kim","year":"2001","unstructured":"Kim, J. S. et al. Development of a packaging cell line for propagation of replication-deficient adenovirus vector. Exp. Mol. Med. 33, 145\u2013149 (2001).","journal-title":"Exp. Mol. Med."},{"key":"10101_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/bit.10644","volume":"83","author":"L Xie","year":"2003","unstructured":"Xie, L. et al. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. Biotechnol. Bioeng. 83, 45\u201352 (2003).","journal-title":"Biotechnol. Bioeng."},{"key":"10101_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/bit.20455","volume":"90","author":"L Maranga","year":"2005","unstructured":"Maranga, L., Aunins, J. G. & Zhou, W. Characterization of changes in PER.C6 cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnol. Bioeng. 90, 645\u2013655 (2005).","journal-title":"Biotechnol. Bioeng."},{"key":"10101_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","volume":"540","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration. Nature 540, 144\u2013149 (2016).","journal-title":"Nature"},{"key":"10101_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136\u2013150 (2020).","journal-title":"Cell"},{"key":"10101_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbrc.2016.11.129","volume":"482","author":"F Dong","year":"2017","unstructured":"Dong, F., Xie, K., Chen, Y., Yang, Y. & Mao, Y. Polycistronic tRNA and CRISPR guide-RNA enables highly efficient multiplexed genome engineering in human cells. Biochem. Biophys. Res. Commun. 482, 889\u2013895 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10101_CR28","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1073\/pnas.1420294112","volume":"112","author":"K Xie","year":"2015","unstructured":"Xie, K., Minkenberg, B. & Yang, Y. Boosting CRISPR\/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Proc. Natl. Acad. Sci. USA. 112, 3570\u20133575 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10101_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000078556","volume":"106","author":"L Bylund","year":"2004","unstructured":"Bylund, L., Kyt\u00f6l\u00e4, S., Lui, W. O., Larsson, C. & Weber, G. Analysis of the cytogenetic stability of the human embryonal kidney cell line 293 by cytogenetic and STR profiling approaches. Cytogenet. Genome Res. 106, 28\u201332 (2004).","journal-title":"Cytogenet. Genome Res."},{"key":"10101_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","volume":"6","author":"N Chirmule","year":"1999","unstructured":"Chirmule, N. et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574\u20131583 (1999).","journal-title":"Gene Ther."},{"key":"10101_CR31","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/sj.gt.3301611","volume":"8","author":"G Cichon","year":"2001","unstructured":"Cichon, G. et al. Complement activation by recombinant adenoviruses. Gene Ther. 8, 1794\u20131800 (2001).","journal-title":"Gene Ther."},{"key":"10101_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/mthe.2002.0669","volume":"6","author":"MT Vlachaki","year":"2002","unstructured":"Vlachaki, M. T. et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 6, 342\u2013348 (2002).","journal-title":"Mol. Ther."},{"key":"10101_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0042-6822(03)00161-2","volume":"311","author":"P Seshidhar Reddy","year":"2003","unstructured":"Seshidhar Reddy, P. et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311, 384\u2013393 (2003).","journal-title":"Virology"},{"key":"10101_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0002-9343(75)90267-3","volume":"59","author":"RL Myerowitz","year":"1975","unstructured":"Myerowitz, R. L. et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am. J. Med. 59, 591\u2013598 (1975).","journal-title":"Am. J. Med."},{"key":"10101_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/bit.22439","volume":"104","author":"KS Sandhu","year":"2009","unstructured":"Sandhu, K. S. & Al-Rubeai, M. The effect of Bcl-2, YAMA, and XIAP over-expression on apoptosis and adenovirus production in HEK293 cell line. Biotechnol. Bioeng. 104, 752\u2013765 (2009).","journal-title":"Biotechnol. Bioeng."},{"key":"10101_CR36","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1128\/JVI.78.12.6200-6208.2004","volume":"78","author":"P Murakami","year":"2004","unstructured":"Murakami, P. et al. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J. Virol. 78, 6200\u20136208 (2004).","journal-title":"J. Virol."},{"key":"10101_CR37","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/bit.27679","volume":"118","author":"J Lavado-Garcia","year":"2021","unstructured":"Lavado-Garcia, J. et al. Metabolic engineering of HEK293 cells to improve transient transfection and cell budding of HIV-1 virus-like particles. Biotechnol. Bioeng. 118, 1649\u20131663 (2021).","journal-title":"Biotechnol. Bioeng."},{"key":"10101_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201900562","volume":"15","author":"AS Formas-Oliveira","year":"2020","unstructured":"Formas-Oliveira, A. S., Basilio, J. S., Rodrigues, A. F. & Coroadinha, A. S. Overexpression of ER protein processing and apoptosis regulator genes in human embryonic kidney 293 cells improves gene therapy vectors production. Biotechnol. J. 15, e1900562 (2020).","journal-title":"Biotechnol. J."},{"key":"10101_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1021\/bp025572x","volume":"19","author":"CB Elias","year":"2003","unstructured":"Elias, C. B. et al. Improving glucose and glutamine metabolism of human HEK 293 and Trichoplusia ni insect cells engineered to express a cytosolic pyruvate carboxylase enzyme. Biotechnol. Prog. 19, 90\u201397 (2003).","journal-title":"Biotechnol. Prog."},{"key":"10101_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jbiotec.2013.11.002","volume":"169","author":"C Vallee","year":"2014","unstructured":"Vallee, C., Durocher, Y. & Henry, O. Exploiting the metabolism of PYC expressing HEK293 cells in fed-batch cultures. J. Biotechnol. 169, 63\u201370 (2014).","journal-title":"J. Biotechnol."},{"key":"10101_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/bit.25691","volume":"113","author":"AF Rodrigues","year":"2016","unstructured":"Rodrigues, A. F. et al. Increased titer and reduced lactate accumulation in recombinant retrovirus production through the down-regulation of HIF1 and PDK. Biotechnol. Bioeng. 113, 150\u2013162 (2016).","journal-title":"Biotechnol. Bioeng."},{"key":"10101_CR42","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/jvi.71.9.6381-6389.1997","volume":"71","author":"A Webster","year":"1997","unstructured":"Webster, A., Leith, I. R., Nicholson, J., Hounsell, J. & Hay, R. T. Role of preterminal protein processing in adenovirus replication. J. Virol. 71, 6381\u20136389 (1997).","journal-title":"J. Virol."},{"key":"10101_CR43","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.1073\/pnas.91.24.11537","volume":"91","author":"MT Armentero","year":"1994","unstructured":"Armentero, M. T., Horwitz, M. & Mermod, N. Targeting of DNA polymerase to the adenovirus origin of DNA replication by interaction with nuclear factor I. Proc. Natl. Acad. Sci. USA. 91, 11537\u201311541 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10101_CR44","doi-asserted-by":"publisher","first-page":"18634","DOI":"10.1016\/S0021-9258(17)44799-5","volume":"265","author":"M Chen","year":"1990","unstructured":"Chen, M., Mermod, N. & Horwitz, M. S. Protein-protein interactions between adenovirus DNA polymerase and nuclear factor I mediate formation of the DNA replication preinitiation complex. J. Biol. Chem. 265, 18634\u201318642 (1990).","journal-title":"J. Biol. Chem."},{"key":"10101_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79998-1","volume":"11","author":"J Lee","year":"2021","unstructured":"Lee, J. et al. Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein. Sci. Rep. 11, 856 (2021).","journal-title":"Sci. Rep."},{"key":"10101_CR46","first-page":"775","volume":"2","author":"Q Wang","year":"1995","unstructured":"Wang, Q., Jia, X. C. & Finer, M. H. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2, 775\u2013783 (1995).","journal-title":"Gene Ther."},{"key":"10101_CR47","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1128\/jvi.70.9.6497-6501.1996","volume":"70","author":"DE Brough","year":"1996","unstructured":"Brough, D. E., Lizonova, A., Hsu, C., Kulesa, V. A. & Kovesdi, I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497\u20136501 (1996).","journal-title":"J. Virol."},{"key":"10101_CR48","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1128\/JVI.72.3.2022-2032.1998","volume":"72","author":"M Lusky","year":"1998","unstructured":"Lusky, M. et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1\/E2A, or E1\/E4 deleted. J. Virol. 72, 2022\u20132032 (1998).","journal-title":"J. Virol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10101-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:02:51Z","timestamp":1783645371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10101"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10101-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"939"}}